866-997-4948(US-Canada Toll Free)

Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010

Published By :

GlobalData

Published Date : Oct 2010

Category :

Competitive Analysis

No. of Pages : 79 Pages


GlobalData\'s Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q3 2010 report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&As) and financings in the pharmaceuticals industry. The report provides detailed information on partnership and licensing transactions, M&As, equity/debt offerings, private equity, and venture financing registered in the pharmaceuticals industry in Q3 2010. 

The report portrays detailed comparative data on the number of deals and their value in the last five quarters, subdivided by deal types, various therapy areas, and geographies. Additionally, the report provides information on the top financial advisory firms in the pharmaceuticals industry.

Data presented in this report is derived from GlobalDatas proprietary in-house Pharmaceuticals eTrack deals database and primary and secondary research.

Scope

  • Analysis of the market trends for the pharmaceutical industry in the global arena. 
  • Review of deal trends in the cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, and women\'s health segments.
  • Analysis of partnerships, licensing, M&As, equity/debt offerings, private equity, and venture financing deals in the pharmaceutical industry.
  • Analysis of therapy areas which are very active in terms of venture capital financing, partnerships, licensing agreements, equity/debt offerings, and M&As.
  • Analysis of deals based on different payment modes, including upfront and milestone payments, primarily in partnerships and licensing agreements in the pharmaceutical industry.
  • Analysis of partnership and licensing deals based on clinical stage of development of products.
  • Summary of the pharmaceutical deals globally in the last five quarters.
  • Information on the top deals happened in the pharmaceutical industry.
  • Geographies covered include North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa.
  • League tables of financial advisors in M&As and equity/debt offerings. This includes key advisors such as Morgan Stanley, Credit Suisse, and Goldman Sachs.

Reasons to buy

  • Enhance your decision making capability in a more rapid and time sensitive manner.
  • Find out the major deal performing segments for investments in your industry.
  • Evaluate the types of companies which are entering into partnership or licensing agreements; divesting and acquiring assets.
  • Identify companies that are aggressively looking to raise capital in the market
  • Evaluate niche therapy areas that are receiving majority of the upfront and milestone payments in the pharmaceutical industry.
  • Identify the key venture capitalists, who are financing the pharmaceutical and biotech companies.
  • Evaluate the clinical development stages where majority of the partnerships and licensing agreements are happening.
  • Do deals with an understanding of how competitors are financed, and the mergers and partnerships that have shaped the pharmaceutical industry.
  • Identify growth segments and opportunities in each region within the industry.
  • Look for key financial advisors where you are planning to raise capital from the market or for acquisitions within the industry.
Table of Content

1 Table of Contents 2

1.1 List of Tables 4
1.2 List of Figures 6

2 Deal Summary 8
2.1 Pharmaceuticals & Healthcare, Global Deals Analysis, Q3 2010 8
2.2 Pharmaceuticals & Healthcare, Global, by Type, Number of Deals and Deal Value, Q3 2010 10
2.3 Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2010 11
2.3.1 Reckitt Benckiser To Acquire SSL 11
2.3.2 Carlyle Group Completes Acquisition Of NBTY 11
2.3.3 Johnson & Johnson To Acquire Additional Stake In Crucell 11
2.3.4 Covance Enters Into An Agreement With Sanofi-Aventis 12
2.3.5 Gilead Sciences Completes Private Placement Of Senior Notes For $2,200 Million 12

3 Pharmaceuticals & Healthcare, Deals Summary, by Type 13
3.1 Pharmaceuticals & Healthcare, Global, M&A, Q3 2010 13
3.1.1 Top M&A Deals in Q3 2010 14
3.1.2 Pharmaceuticals & Healthcare, Global M&A Deals, by Therapy Area, Q3 2009 - Q3 2010 15
3.2 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Q3 2010 16
3.2.1 Top Initial Public Offerings in Q3 2010 17
3.2.2 Top Secondary Offerings in Q3 2010 17
3.2.3 Top PIPE Deals in Q3 2010 17
3.2.4 Pharmaceuticals & Healthcare, Global, IPO deals, Q4 2009 Q3 2010 18
3.2.5 Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Q3 2009 Q3 2010 19
3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Q3 2010 20
3.3.1 Top Public Debt Offerings in Q3 2010 21
3.3.2 Top Private Debt Placements in Q3 2010 21
3.3.3 Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Q3 2009 - Q3 2010 22
3.4 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, Q3 2010 23
3.4.1 Top Venture Financing Deals in Q3 2010 24
3.4.2 Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q3 2010 25
3.4.3 Pharmaceuticals & Healthcare, Global, Venture Capital, by Therapy Area, Q3 2009 - Q3 2010 26
3.4.4 Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Q4 2009 Q3 2010 27
3.4.5 Pharmaceuticals & Healthcare, Global, Top VC Backed Companies, Q3 2010 28
3.5 Pharmaceuticals & Healthcare, Global Private Equity Deals, Q3 2010 29
3.5.1 Top Private Equity Deals in Q3 2010 30
3.5.2 Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Q3 2009 - Q3 2010 31

4 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
4.1 Pharmaceuticals & Healthcare, Global, Partnership Deals, Q3 2010 32
4.2 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Q3 2009 - Q3 2010 33
4.3 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2010 34
4.3.1 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Deal Value, Q3 2010 35
4.3.2 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
4.3.3 Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
4.4 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
4.5 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 38
4.6 Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39

5 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
5.1 Pharmaceuticals & Healthcare, Global, Licensing Agreements, Q3 2010 40
5.2 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
5.2.1 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Deal Value, Q3 2010 42
5.2.2 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q3 2010 42
5.2.3 Pharmaceuticals & Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q3 2010 43
5.2.4 Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 Q3 2010 43
5.3 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q3 2009 - Q3 2010 44
5.4 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
5.5 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q3 2009 - Q3 2010 46
5.6 Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q3 2009 - Q3 2010 47

6 Deal Summary by Therapy Area 48
6.1 Pharmaceuticals & Healthcare, Oncology Deals, Q3 2010 48
6.1.1 Oncology Deals of the Quarter 49
6.2 Pharmaceuticals & Healthcare, Central Nervous System Deals, Q3 2010 50
6.2.1 Central Nervous System Deals of the Quarter 51
6.3 Pharmaceuticals & Healthcare, Infectious Disease Deals, Q3 2010 52
6.3.1 Infectious Disease Deals of the Quarter 53
6.4 Pharmaceuticals & Healthcare, Immunology Deals, Q3 2010 54
6.4.1 Immunology Deals of the Quarter 55
6.5 Pharmaceuticals & Healthcare, Cardiovascular Deals, Q3 2010 56
6.5.1 Cardiovascular Deals of the Quarter 57
6.6 Pharmaceuticals & Healthcare, Metabolic Disorders Deals, Q3 2010 58
6.6.1 Metabolic Disorders Deals of the Quarter 59
6.7 Pharmaceuticals & Healthcare, Musculoskeletal Deals, Q3 2010 60
6.7.1 Musculoskeletal Deals of the Quarter 61
6.8 Pharmaceuticals & Healthcare, Respiratory Deals, Q3 2010 62
6.8.1 Respiratory Deals of the Quarter 63
6.9 Pharmaceuticals & Healthcare, Gastrointestinal Deals, Q3 2010 64
6.9.1 Gastrointestinal Deals of the Quarter 65
6.10 Pharmaceuticals & Healthcare, Dermatology Deals, Q3 2010 66
6.10.1 Dermatology Deals of the Quarter 67

7 Deal Summary by Geography 68
7.1 Pharmaceuticals & Healthcare, North America Region Deals, Q3 2010 68
7.1.1 North America Deals of the Quarter 69
7.2 Pharmaceuticals & Healthcare, Europe Region Deals, Q3 2010 70
7.2.1 Europe Deals of the Quarter 71
7.3 Pharmaceuticals & Healthcare, Asia-Pacific Deals, Q3 2010 72
7.3.1 Asia-Pacific Deals of the Quarter 73
7.4 Pharmaceuticals & Healthcare, Rest of the World Deals, Q3 2010 74
7.4.1 Rest of the World Deals of the Quarter 75

8 Pharmaceuticals & Healthcare, Top Advisors 76
8.1 Pharmaceuticals & Healthcare, Global Top Financial Advisors, M&A, Q4 2009 - Q3 2010 76
8.2 Pharmaceuticals & Healthcare, Top Financial Advisors, Equity Offerings, Q4 2009 - Q3 2010 77

9 Further Information 78
9.1 Methodology 78
9.2 About GlobalData 78
9.3 Contact Us 79
9.4 Disclosure information 79
9.5 Disclaimer 79

List of Table


Table 1: Pharmaceuticals & Healthcare, Global, Deals Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 9
Table 2: Pharmaceuticals & Healthcare, Global, Number Of Deals and Deal Value (%), Q3 2010 10
Table 3: Pharmaceuticals & Healthcare, Global, Top Deals, Q3 2010 11
Table 4: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 Q3 2010 13
Table 5: Pharmaceuticals & Healthcare, Global, Top M&A Deals, Q3 2010 14
Table 6: Pharmaceuticals & Healthcare, Global, M&A, Deals Summary, Number of Deals and Deal Value (US$ m), by Therapy Area, , Q3 2009 - Q3 2010 15
Table 7: Pharmaceuticals & Healthcare, Global, Equity Offerings, Deals Summary, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 16
Table 8: Pharmaceuticals & Healthcare, Global, Top Initial Public Offering Deals, Q3 2010 17
Table 9: Pharmaceuticals & Healthcare, Global, Top Secondary Offering Deals, Q3 2010 17
Table 10: Pharmaceuticals & Healthcare, Global, Top PIPE Deals, Q3 2010 17
Table 11: Pharmaceuticals & Healthcare, Global, IPO Deals, Q4 2009 Q3 2010 18
Table 12: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Deals Summary, Number of Deals and Deal Value (US$m), , Q3 2009 - Q3 2010 19
Table 13: Pharmaceuticals & Healthcare, Global, Debt Offering, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 20
Table 14: Medical Equipment, Global, Top Public Debt Offerings, Q3 2010 21
Table 15: Medical Equipment, Global, Top Private Debt Placements, Q3 2010 21
Table 16: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 22
Table 17: Pharmaceuticals & Healthcare, Global, Venture Capital, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Table 18: Pharmaceuticals & Healthcare, Global, Top Venture Capital Deals, Q3 2010 24
Table 19: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Value (%), Q3 2010 25
Table 20: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Deals Summary, Q3 2009 - Q3 2010 26
Table 21: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q3 2009 Q3 2010 27
Table 22: Pharmaceuticals and Healthcare, Global, Top VC Backed Companies, April 2010 September 2010 28
Table 23: Pharmaceuticals & Healthcare, Global, Private Equity, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 Q3 2010 29
Table 24: Pharmaceuticals & Healthcare, Global, Top Private Equity Deals, Q3 2010 30
Table 25: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Deals Summary, Q3 2009 - Q3 2010 31
Table 26: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Table 27: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Table 28: Pharmaceuticals & Healthcare, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Table 29: Pharmaceuticals & Healthcare, Global, Partnerships, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2010 35
Table 30: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q3 2010 35
Table 31: Pharmaceuticals & Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q3 2010 36
Table 32: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Table 33: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Table 34: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Table 35: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Table 36: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Deals Summary, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Table 37: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Deal Value, Q3 2010 42
Table 38: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q3 2010 42
Table 39: Pharmaceuticals & Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q3 2010 43
Table 40: Pharmaceuticals & Healthcare, Global, Licensing Agreements with Equity Investment, Q3 2009 Q3 2010 43
Table 41: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Table 42: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment (US$ m), Q3 2009 - Q3 2010 45
Table 43: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 46
Table 44: Pharmaceuticals & Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Table 45: Pharmaceuticals & Healthcare, Global, Oncology, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 49
Table 46: Pharmaceuticals & Healthcare, Global, Central Nervous System, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 51
Table 47: Pharmaceuticals & Healthcare, Global, Infectious Disease, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 53
Table 48: Pharmaceuticals & Healthcare, Global, Immunology, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 55
Table 49: Pharmaceuticals & Healthcare, Global, Cardiovascular, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 57
Table 50: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 59
Table 51: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 61
Table 52: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 63
Table 53: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Table 54: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Table 55: Pharmaceuticals & Healthcare, North America, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 69
Table 56: Pharmaceuticals & Healthcare, Europe, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 71
Table 57: Pharmaceuticals & Healthcare, Asia-Pacific, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 73
Table 58: Pharmaceuticals & Healthcare, Rest of the World, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Table 59: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 76
Table 60: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q3 2010 77

List of Chart


Figure 1: Pharmaceuticals & Healthcare, Global, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 8
Figure 2: Pharmaceuticals & Healthcare, Global, Number Of Deals (%) and Deal Value (%), Q3 2010 10
Figure 3: Pharmaceuticals & Healthcare, Global, M&A, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 13
Figure 4: Pharmaceuticals & Healthcare, Global, M&A, by Therapy Area, Number of Deals and Deal Value (US$m), by Therapy Area, Q3 2009 Q3 2010 15
Figure 5: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 16
Figure 6: Pharmaceuticals & Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$m), , Q3 2009 Q3 2010 19
Figure 7: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Value (US$m), Q3 2009 - Q3 2010 20
Figure 8: Pharmaceuticals & Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), , Q3 2009 - Q3 2010 22
Figure 9: Pharmaceuticals & Healthcare, Global, Venture Capital, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 23
Figure 10: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Value (%), Q3 2010 25
Figure 11: Pharmaceuticals & Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 26
Figure 12: Pharmaceuticals & Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Value (US$ m), Q4 2009 Q3 2010 27
Figure 13: Pharmaceuticals & Healthcare, Global, Private Equity, Number of Deals and Deal Value (US$ m), Q3 2009 Q3 2010 29
Figure 14: Pharmaceuticals & Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), by Therapy Area, Q3 2009 - Q3 2010 31
Figure 15: Pharmaceuticals & Healthcare, Global, Partnerships, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 32
Figure 16: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 33
Figure 17: Pharmaceuticals & Healthcare, Global, Partnership Deals, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 34
Figure 18: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 37
Figure 19: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, Q3 2009 - Q3 2010 38
Figure 20: Pharmaceuticals & Healthcare, Global, Partnership Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 39
Figure 21: Pharmaceuticals & Healthcare, Global, Licensing Agreements, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 40
Figure 22: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 41
Figure 23: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 44
Figure 24: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 45
Figure 25: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 46
Figure 26: Pharmaceuticals & Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront & Milestone Payment and Deal Value (US$ m), Q3 2009 - Q3 2010 47
Figure 27: Pharmaceuticals & Healthcare, Global, Oncology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 48
Figure 28: Pharmaceuticals & Healthcare, Global, Central Nervous System, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 50
Figure 29: Pharmaceuticals & Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 52
Figure 30: Pharmaceuticals & Healthcare, Global, Immunology, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 54
Figure 31: Pharmaceuticals & Healthcare, Global, Cardiovascular, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 56
Figure 32: Pharmaceuticals & Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 58
Figure 33: Pharmaceuticals & Healthcare, Global, Musculoskeletal, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 60
Figure 34: Pharmaceuticals & Healthcare, Global, Respiratory, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 62
Figure 35: Pharmaceuticals & Healthcare, Global, Gastrointestinal, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 64
Figure 36: Pharmaceuticals & Healthcare, Global, Dermatology, Deals Summary, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 66
Figure 37: Pharmaceuticals & Healthcare, North America, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 68
Figure 38: Pharmaceuticals & Healthcare, Europe, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 70
Figure 39: Pharmaceuticals & Healthcare, Asia-Pacific, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 72
Figure 40: Pharmaceuticals & Healthcare, Rest of the World, Number of Deals and Deal Value (US$ m), Q3 2009 - Q3 2010 74
Figure 41: Pharmaceuticals & Healthcare, Top Financial Advisors, M&A, Number of Deals and Deal Value (US$ m), Q3 2010 76
Figure 42: Pharmaceuticals & Healthcare, Global Top Financial Advisors, Equity Offerings, Number of Deals and Deal Value (US$ m), Q4 2009 - Q3 2010 77

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *